Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01522456 · ClinicalTrials.gov registry record · Phase 4
Split-face Tolerability Comparison Between Adapalene-Benzoyl Peroxide Gel Versus Tretinoin Gel
A Phase 4 study, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 4
- Development phase
- 73
- Enrollment target
NCT01522456 is a Phase 4 study that has completed, run by Galderma R&D. The registered enrollment target is 73 participants.
The verdict
NCT01522456, a Phase 4 study, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 73 participants
- Enrollment target
Study Summary
To compare the tolerability of Epiduo® (adapalene and benzoyl peroxide) Gel 0.1%/2.5% to Retin-A Micro® (tretinoin gel) microsphere when used by subjects with acne vulgaris for 3 weeks in terms of local tolerability parameters (erythema, dryness, scaling, stinging/burning) and preference.
Interventions
- DRUG Epiduo Gel
- DRUG Retin-A Micro Microsphere 0.1%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2012-04 |
| Est. Completion | 2012-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01522456
The ClinicalTrials.gov registry entry for NCT01522456 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Epiduo Gel is the first listed.
NCT01522456 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01522456 about?
NCT01522456 is a clinical study titled "Split-face Tolerability Comparison Between Adapalene-Benzoyl Peroxide Gel Versus Tretinoin Gel". To compare the tolerability of Epiduo® (adapalene and benzoyl peroxide) Gel 0.1%/2.5% to Retin-A Micro® (tretinoin gel) microsphere when used by subjects with acne vulgaris for 3 weeks in terms of local tolerability parameters (erythema, dryness, scaling, stinging/burning) and preference.
What is the current status of trial NCT01522456?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 73 participants. The study started on 2012-04. Estimated completion is 2012-05.
What interventions are being tested in trial NCT01522456?
The interventions under investigation include: Epiduo Gel (DRUG), Retin-A Micro Microsphere 0.1% (DRUG).
Who is sponsoring clinical trial NCT01522456?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.